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ORIGINAL ARTICLE

A dietary intervention for chronic diabetic neuropathy
pain: a randomized controlled pilot study
AE Bunner1, CL Wells1, J Gonzales1, U Agarwal2, E Bayat3 and ND Barnard1,4
BACKGROUND: Diabetic neuropathy is a common and often debilitating condition for which available treatments are limited.
Because a low-fat plant-based diet has been shown to improve glycemic control in individuals with type 2 diabetes, we
hypothesized that such a diet would reduce painful symptoms of diabetic neuropathy.
METHODS: In this 20-week pilot study, individuals with type 2 diabetes and painful diabetic neuropathy were randomly assigned to
two groups. The intervention group was asked to follow a low-fat, plant-based diet, with weekly classes for support in following the
prescribed diet, and to take a vitamin B12 supplement. The control group was asked to take the same vitamin B12 supplement, but
received no other intervention. At baseline, midpoint and 20 weeks, clinical, laboratory and questionnaire data were collected.
Questionnaires included an analog ‘worst pain’ scale, Michigan Neuropathy Screening Instrument, global impression scale, Short
Form McGill Pain Questionnaire, Neuropathy Total Symptom Score, a weekly pain diary and Norfolk Quality of Life Questionnaire.
RESULTS: After 20 weeks, body weight change with the intervention was − 6.4 kg (95% conﬁdence interval (CI) − 9.4 to − 3.4,
Po 0.001) in an effect size analysis. Electrochemical skin conductance in the foot improved by an average of 12.4 microseimens
(95% CI 1.2–23.6, P = 0.03) with the intervention in an effect size analysis. The between-group difference in change in pain, as
measured by the McGill pain questionnaire, was − 8.2 points (95% CI − 16.1 to − 0.3, P = 0.04). Michigan Neuropathy Screening
Instrument questionnaire score change was − 1.6 points (95% CI − 3.0 to − 0.2, P = 0.03).
CONCLUSIONS: Improvements were seen in some clinical and pain measures. This pilot study suggests the potential value of a
plant-based diet intervention, including weekly support classes, for treating painful diabetic neuropathy.
Nutrition & Diabetes (2015) 5, e158; doi:10.1038/nutd.2015.8; published online 26 May 2015

BACKGROUND
Diabetic peripheral neuropathy occurs in up to 60% of individuals
with type 2 diabetes1 and is associated with signiﬁcant morbidity,
including gait disturbances, amputations, anxiety, depression and
reduced quality of life.2,3 The condition manifests with damage to
the terminal branches of peripheral nerves and usually ﬁrst affects
small ﬁbers that are responsible for translating pain, light touch
and temperature. As neuropathy progresses, large ﬁbers responsible for reﬂexes and muscle tone are affected, leading to balance
and gait problems. Most patients with diabetic peripheral
neuropathy present with pain, numbness, or abnormal, spontaneous or induced sensations in the lower extremities. Pain occurs
in 15–30% of cases.4
Plant-based dietary interventions typically improve glycemic
control and other factors associated with type 2 diabetes
and its complications. In a study of 99 type 2 diabetes patients
comparing a low-fat plant-based diet with a more conventional
diet, in an analysis limited to participants making no medication
changes, HbA1c (percent hemoglobin A1c) fell by 1.2 points
in the plant-based group, compared with 0.4 points in the
control group.5 Glycemic control appears to have a key role
in the risk of complications.6 In intervention trials using plantbased diets, improvements in glycemic control,6 blood lipid
concentrations7 and blood pressure8 have been consistently
observed,6–8 and diet acceptability is similar to that of other
therapeutic diets.9

Two uncontrolled diet intervention studies showed promising
results in individuals with diabetic neuropathy.10,11 We therefore
hypothesized that a plant-based dietary intervention can reduce
diabetic neuropathy pain and conducted a randomized, controlled, pilot study to test this hypothesis. This study was intended
to investigate the efﬁcacy of this approach and the suitability of
the overall method, permitting larger trials to follow. The study
was not intended to elucidate the mechanisms by which a dietary
intervention might lead to clinical changes or to separate which
parts of the intervention might be responsible for any observed
beneﬁt.
MATERIALS AND METHODS
Participants and recruitment
Participants were recruited in the Washington, DC, area through local
physicians and media outlets in two replications. Inclusion criteria were
age 18–65 years, diagnosis of type 2 diabetes, and diagnosis or symptoms
of painful diabetic neuropathy for at least 6 months. Exclusion criteria were
vitamin B12 deﬁciency, alcohol consumption of more than two drinks
per day, use of recreational drugs in the past 6 months, pregnancy,
unstable medical or psychiatric illness, current adherence to a vegan diet
and inability or unwillingness to participate in all components of the study.
Participants were screened for B12 deﬁciency, which can cause neuropathy
independent of diabetes, by a B12 blood level test and a serum
methylmalonic acid12 test. Criteria for deﬁciency were a B12 level of
o200 pg ml−1 or a B12 level of o400 pg ml−1 in combination with MMA
level 4270 nmol ml−1.12
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A screening interview was conducted to determine eligibility. Participants were determined to have symptoms of painful diabetic neuropathy
if they described in the screening interview painful sensations in the hands
or feet, including tingling, burning or freezing. The study was approved by
Ethical and Independent Review Services. All participants signed a consent
form. The trial was registered at Clinicaltrials.gov under NCT01690962 and
NCT01953757.
Thirty-ﬁve participants were assigned to the intervention or control
groups by study staff using an allocation sequence generated from a
random number table. For the ﬁrst replication, allocation concealment was
achieved using sealed envelopes. Participants in the second replication
were stratiﬁed by Neuropathy Total Symptom Scores in blocks of two.13
Since those assignments were done simultaneously, allocation concealment was not required. It was not possible to blind participants and
instructors to group assignment. However, examinations for the Michigan
Neuropathy Screening Instrument14 and Neuropathy Impairment ScoreLower Limb15 were performed by an independent blinded clinician who
was impartial to the study hypothesis.

Study design and procedures
The intervention group was instructed to follow the intervention diet and
attend weekly nutrition classes offering education and social support for
20 weeks. The study duration was chosen to be comparable to that of
previous studies demonstrating clinically signiﬁcant effects of plant-based
diets on type 2 diabetes.16 The intervention diet omitted animal products,
limited fat intake to 20–30 g day−1 and favored low-glycemic index foods.
The diet focused on vegetables, fruits, grains and legumes. Example meals
included oatmeal with raisins, pasta with marinara sauce, vegetable stir-fry
with rice and lentil stew. In addition, participants were asked to take a
provided daily tablet of 1000 mcg methylcobalamin (vitamin B12).
The control group was asked to take the same provided vitamin B12
supplement daily but was asked to make no major diet changes during the
20-week study period. The B12 supplement was intended to prevent B12
deﬁciency in intervention-group participants, should they elect to continue
the prescribed diet long term, and also to provide a credible placebo for
the control group.16 Assessments occurred at baseline, 10 weeks and
20 weeks.
Participants were asked to keep their diabetes medications constant
when possible, but to follow the advice of their personal physicians
regarding medication use (for example, in the case of hypoglycemia).

Dependent variables
Dietary changes were assessed through the use of 2-day dietary records
analyzed by a registered dietitian. Body weight was measured in light
clothing and without shoes using a digital scale accurate to 0.1 kg. Blood
pressure was measured 3 times, using a digital sphygmomanometer. The
ﬁrst measurement was disregarded, and the mean of the remaining two
measurements was calculated. Blood glucose, HbA1c (percent hemoglobin
A1c) and plasma lipid concentrations were measured by standard methods
at Quest Diagnostics (Baltimore, MD, USA).
Sensory perception was assessed by monoﬁlament sensation, vibration
perception and ankle reﬂex as part of the Michigan Neuropathy Screening
Instrument physical assessment (MNSI-PA, this instrument also includes a
questionnaire ﬁlled out by the patient, as noted below), and pin-prick and
touch pressure were assessed as part of the Neuropathy Impairment ScoreLower Limb.14,15 Electrochemical skin conductance was measured by a
Sudoscan device, which evaluates each foot and each hand.17,18
Electrochemical skin conductance is a measure of sudomotor nerve
function, and is correlated with pain.19
Our primary outcomes were pain and sensory symptoms as measured
by visual analog ‘worst pain’ scale, global impression scale,20 Short Form
McGill Pain Questionnaire,21,22 Michigan Neuropathy Screening Instrument
questionnaire (MNSI-Q), Neuropathy Total Symptom Score, a weekly pain
diary, and Norfolk Quality of Life Questionnaire.23,24 The visual analog scale
was a 10-cm line anchored by ‘No pain’ and ‘Pain as bad as it could
possibly be’ on either end, and participants were asked to rate their worst
pain in the preceding 2 weeks. The visual analog scale was completed with
an interviewer, but all other questionnaires were completed
independently.
The patient’s global impression of change (PGIC) question assesses
subjective pain improvement by asking participants to rate symptom
change on a scale of 1–7 from ‘no change’ to ‘a great deal better.20
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Pain diaries have been used in diabetic neuropathy clinical trials to track
pain over time.25 Participants were asked to provide weekly ratings for
average pain, worst pain and night pain on an 11-point numerical scale.
Mood and depression were measured by the Beck Depression Inventory
(BDI)26 and the Center for Epidemiological Studies Depression revised
scale.27 The BDI measures symptom severity, while the Center for
Epidemiological Studies Depression revised scale measures symptom
frequency.

Statistical analysis
Since little has been published on the effects of a plant-based diet on pain
in diabetic neuropathy and no prior controlled studies using a plant-based
diet were found, a power analysis could not be based on the previous
research. Previous studies were conducted on pre-diabetes patients10 or in
a short-term residential program with no control group.11 Therefore, we
chose an exploratory approach that did not limit sample size and accepted
all volunteers who met the participation criteria.
For pain scales, body weight and lipid concentrations (total cholesterol,
low density lipoprotein-cholesterol, high density lipoprotein-cholesterol
and triglycerides), baseline descriptive statistics were calculated. For
normally distributed data, two-tailed Student’s T-tests for independent
samples were calculated for 20-week changes in the diet and control
groups. Since primary outcomes were based on the 20-week study
endpoint, statistical approaches that evaluate changes over time were not
used. For non-normally distributed variables, Wilcoxon signed-rank tests
were used. Chi-squared tests were used for categorical variables. An alpha
of 0.05 was used for all statistical tests. Baseline values for key outcome
variables were included as covariates in the main assessments of the effect
of diet in the multivariate analysis of covariance.
For missing data in a reporting period, values from the previous period
were brought forward. For body weight, drop-outs were considered to
have returned to baseline weights.

RESULTS
Recruitment
Seventy-one participants were interviewed and thirty-ﬁve were
enrolled (Figure 1). Recruitment periods were November 2012 to
January 2013 and October 2013 to January 2014. Among
volunteers who were excluded or withdrew, compared with
enrolled participants, fewer (4%) were Hispanic, more (64%) were
black and fewer (31%) were white. One control-group participant
was excluded from the data analysis on the basis of B12

Figure 1. Recruitment and retention. Study completers attended the
ﬁnal assessment at 20 weeks. All but one participant were included
in the analysis.
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Table 1.

Baseline characteristics

Variable
Women, N
College degree, N
Black race, N
Hispanic, N
Age, years
Weight, kg
BMI, kg m−2
Diabetes duration, years
Total cholesterol, mg dl−1
Triglycerides, mg dl−1
HbA1c, %
HbA1c, mmol ml−1
Fasting glucose, mg dl−1
MNSI-PA
NIS-LL
Visual analog scale, cm
MPQ-T
QOL-T
NTSS-6
On metformin
On insulin
On other agents

All particiants
(N = 34)

Intervention group
(N = 17)

Supplement group
(N = 17)

Pvalue*

19
18
16
5
57 (6)a
104 (23)
36 (6)
14 (10)
172 (44)
152 (77)
7.9 (1.6)
63 (18)
159 (66)
4.1 (2.3)
8.9 (6.9)
5.5 (2.6)
22 (10)
29 (15)
12 (5)
24
15
17

11 (65%)
10 (59%)
5 (29%)
1 (6%)
57 (6)
102 (23)
36 (6)
15 (11)
171 (48)
151 (66)
8.0 (1.7)
64 (19)
161 (74)
4.8 (2.4)
11.3 (8.0)
5.3 (2.7)
23 (11)
28 (14)
11 (5)
12 (71%)
6 (35%)
10 (59%)

8 (47%)
8 (47%)
11 (65%)
4 (24%)
58 (6)
106 (24)
36 (7)
12 (10)
173 (41)
153 (89)
7.8 (1.6)
62 (18)
157 (60)
3.4 (2.2)
6.6 (4.6)
5.8 (2.4)
21 (10)
30 (16)
12 (5)
12 (71%)
9 (53%)
7 (41%)

0.56
0.88
0.09
0.34
0.48
0.70
0.90
0.60
0.89
0.95
0.78
0.78
0.89
0.09
0.05
0.57
0.65
0.74
0.35
0.99
0.30
0.31

Abbreviations: BMI, body mass index; MNSI-PA, Michigan Neuropathy Screening Instrument physical assessment; MPQ-T, Short form McGill Pain Questionnaire
total; NIS-LL, Neuropathy Impairment Score Lower Limb; NTSS-6, Neuropathy Total Symptom Score; QOL-T, Norfolk diabetic neuropathy Quality of Life,
total score. aScalar data are presented as mean (s.d.) *P values from Chi-squared tests or Student’s T-tests.

deﬁciency. The participant group had a mean age of 57 years and
was 56% women, 47% black and 15% Hispanic; 53% of
participants had a college degree or a higher education
(Table 1). There were no signiﬁcant baseline differences between
the two groups except for Neuropathy Impairment Score Lower
Limb (NIS-LL), for which the intervention group had a higher score,
indicating more severe neuropathy. At baseline, ﬁve interventiongroup participants and ﬁve control-group participants were taking
medications for diabetic neuropathy symptoms, including pregabalin, gabapentin, sertraline, duloxetine, bupropion and escitalopram. There were no signiﬁcant study-related adverse effects. The
study ended as per the protocol.
Diet adherence
Two-day diet records conducted at midpoint and 20 weeks
showed that 13 of 17 intervention-group participants avoided all
animal products at the midpoint and endpoint assessments. Of
those 13, 8 reported consuming a low-fat (25% kcal or less from
fat) diet at both time points. An additional three of those thirteen
reported consuming a low-fat diet at one of the two time points.
An additional 2 of the 17 intervention-group participants were
fully compliant with the low-fat guidelines at both assessments,
but reported consuming at least modest amounts of animal
products in one diet record, and two participants were noncompliant with the low-fat guidelines and the plant-based
guidelines. No data on vitamin B12 supplement adherence were
collected.
Changes on clinical measurements
Body weight declined by a mean of 7.0 kg over 20 weeks in the
intervention group, as compared with 0.6 kg in the control group
(P o 0.001, Table 2). Mean HbA1c declined in the intervention
group by 0.8 percentage point over 20 weeks, but remained
unchanged in the control group (P = 0.07). Despite the request
that participants not change medications, several did have
medication adjustments, typically due to hypoglycemia. Glucose-

lowering medications were reduced for 10 intervention-group
participants and increased for two by their primary physicians. In
the control group, glucose-lowering medications were reduced for
one participant and increased for two.
Total cholesterol declined 12.1 mg dl−1 in the intervention
group and 2.2 mg dl−1 in the control group (P = 0.20). Low density
lipoprotein cholesterol declined 7.8 mg dl−1 in the intervention
group, but increased by 0.4 mg dl−1 in the control group (P = 0.35).
Compared with the control group, more intervention group
participants reduced lipid-lowering medications (four vs zero) and
fewer increased lipid-lowering medications (one vs three).
Systolic and diastolic blood pressure fell in both groups, without
a signiﬁcant between-group difference. During the 20 weeks,
blood pressure medications were changed for six interventiongroup participants (two reduced, four increased) and one controlgroup participant (zero reduced, one increased).
An analysis limited to study completers found similar results
(Supplementary Table S1).
Changes in perceived pain and neuropathy symptoms
Average foot conductance as measured by a Sudoscan device
showed a decrease in sudomotor nerve function in the control
group (−11.7 microseimens), but a non-signiﬁcant improvement in
the intervention group (0.7 microseimens, P = 0.03). The decline in
the control group was mostly due to a steep drop in measurements for two participants. A similar ﬁnding was observed in
average hand conductance (P = 0.14).
Pain, as measured by the Short Form McGill Pain Questionnaire,
declined by 9.1 points in the intervention group over 20 weeks
and by 0.9 points in the control group (P = 0.04, Table 2). The
largest decline was seen in the sensory subscore (Supplementary
Table S2). Quality of life improved signiﬁcantly within the
intervention group but changes between group did not reach
statistical signiﬁcance. For the autonomic symptoms subscore
of the quality of life questionnaire, the intervention group
improved signiﬁcantly, while the control group did not (P = 0.05,
Nutrition & Diabetes (2015) 1 – 6
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Baseline

(14.3)
(11.0)
(2.5)
(4.9)
(8.1)
(10.1)

27.9
22.6
7.5
10.7
12.8
11.9

95.5
33.5
159.1
46.8
81.2
3.5
155.7
2.16
134.6
7.2
55
127.9
75.8
65.2
55.7
4.3
8.7
4.0
4.6
19.6
13.5
5.3
6.8
8.6
11.2

(20.1)
(5.7)
(42.6)
(11.4)
(34.2)
(0.9)
(61.6)
(0.19)
(51.6)
(1.4)
(15)
(22.6)
(9.0)
(24.1)
(21.6)
(2.3)
(6.8)
(2.4)
(1.9)
(17.9)
(10.0)
(2.5)
(4.5)
(10.6)
(13.0)

105.6
36.2
173.4
47.4
95.4
4.0
152.6
2.12
157.4
7.8
62
144.4
87.2
73.4
67.6
3.4
6.6
5.8
29.6
21.0
7.7
12.3
11.0
10.8

(5.0)†
(1.5)†
(37.8)
(10.1)‡
(28.9)
(0.7)
(56.2)
(0.17)
(65.0)
(1.2)‡
(13)‡
(22.5)a
(9.4)‡
(10.5)
(13.9)
(1.9)a
(7.3)
(2.8)
(13.6)‡
(11.4)§
(2.4)§
(4.2)§
(8.8)
(6.6)

− 7.0
− 2.4
− 12.1
− 5.2
− 7.8
0.1
4.7
0.01
− 25.9
− 0.8
−9
− 11.5
− 5.7
0.7
2.5
− 0.5
− 2.6
− 1.2
− 8.4
− 9.1
− 2.2
− 3.9
− 4.2
− 0.8

(15.7)
(10.0)
(2.8)
(5.1)
(8.4)
(7.3)

(23.6)
(7.1)
(41.4)
(18.9)
(43.6)
(1.4)
(88.8)
(0.23)
(60.5)
(1.6)
(18)
(21.6)
(14.5)
(16.8)
(23.4)
(2.2)
(4.6)
(2.4)

105.1
36.0
175.6
45.0
95.8
4.3
174.5
2.17
138.2
7.8
62
140.1
84.4
61.7
61.2
2.6
6.8
3.8
3.3
24.6
20.1
7.1
9.1
9.5
8.7

(22.9)
(7.1)
(34.0)
(16.9)
(34.5)
(1.5)
(110.6)
(0.24)
(51.3)
(1.4)
(15)
(19.3)
(10.4)
(24.4)
(25.5)
(1.8)
(5.3)
(2.7)
(1.6)
(17.5)
(12.2)
(2.8)
(4.0)
(7.4)
(9.2)

Mean (s.d.)

− 5.1
-0.9
− 0.6
− 3.2
− 1.5
− 2.1

− 0.6
− 0.2
2.2
− 2.4
0.4
0.3
21.9
0.05
− 19.2
0.0
0
-4.3
− 2.8
− 11.7
− 6.4
− 0.8
0.2
− 2.0
(10.5)a
(11.3)
(1.5)
(3.6)§
(4.5)
(7.8)

(3.5)
(1.2)
(25.6)
(6.9)
(21.0)
(0.6)
(68.9)a
(0.17)a
(55.6)a
(0.9)
(10)
(15.0)
(8.8)
(13.2)‡
(11.7)
(1.7)a
(4.9)
(3.0)‡

Mean (s.d.)

Change scores

− 4.0
− 8.2
− 1.6
− 0.7
− 2.8
1.4

− 6.4
− 2.2
− 14.4
− 2.9
− 8.2
− 0.2
− 17.2
− 0.04
− 6.8
− 0.7
−8
− 7.2
− 2.9
12.4
8.9
0.3
− 2.8
0.8

(−15.1 to 7.1)
(−16.1 to − 0.3)
(−3.0 to − 0.2)
(−3.4 to 2.0)
(−7.6 to 2.1)
(−3.7 to 6.4)

(−9.4 to − 3.4)
(−3.2 to − 1.2)
(−36.9 to 8.2)
(−8.9 to 3.2)
(−25.8 to 9.5)
(−0.6 to 0.2)
(−61.2 to 26.8)
(−0.16 to 0.08)
(−49.0 to 35.5)
(−1.5 to 0.1)
(−16 to 1)
(−20.6 to 6.2)
(−9.2 to 3.5)
(1.2 to 23.6)
(−3.2 to 21.0)
(−1.0 to 1.5)
(−7.1 to 1.6)
(−1.3 to 2.8)

Mean (95% CI)

Effect size

o0.001
o0.001
0.20
0.34
0.35
0.36
0.43
0.51
0.75
0.07
0.07
0.28
0.36
0.03
0.14
0.67
0.20
0.45
0.05
0.43
0.04
0.03
0.59
0.26
0.59

P-value*

Abbreviations: BDI, Beck Depression Inventory; BP, blood pressure; CI, conﬁdence interval; CESD-R, Center for Epidemiological Studies, depression scale revised; HDL, high density lipoprotein; LDL, low density
lipoprotein; MNSI-PA, Michigan Neuropathy Screening Instrument physical assessment; MNSI-Q, Michigan Neuropathy Screening Instrument questionnaire; NIS-LL, Neuropathy Impairment Score Lower Limb;
NTSS-6, Neuropathy Total Symptom Score; PGIC, Patients’ Global Impression of Change; Ratio, total cholesterol/HDL; SF, short form; VAS, visual analog pain (worst pain lost two weeks); *Student’s T-test;
†
P o0.0001; §Po0.01; ‡Po0.05. aData are non-normally distributed based on Shapiro-Wilk test. bFoot and hand conductance in microseimens. cSince no PGIC measurement was taken at baseline, some statistics
were not calculated.

(22.7)
(6.0)
(48.4)
(15.1)
(38.3)
(1.1)
(66.3)
(0.19)
(73.5)
(1.7)
(19)
(17.0)
(9.7)
(29.5)
(28.0)
(2.4)
(8.0)
(2.7)

102.5
35.9
171.2
52.1
89.0
3.4
151.0
2.14
160.6
8.0
64
139.3
81.5
64.5
53.2
4.8
11.3
5.3

Mean (s.d.)

20 weeks

Mean (s.d.)

20 weeks
Mean (s.d.)

Baseline
Mean (s.d.)

Change scores

Supplement group

Intervention group

Intervention effects on clinical measures, intention-to-treat analysis

Body weight (kg) (N = 34)
BMI (N = 34)
Total cholesterol (mg dl−1) (N = 34)
HDL (N = 34)
LDL (N = 34)
Ratio (N = 34)
Triglycerides (N = 34)
Log triglycerides (N = 34)
Fasting glucose (N = 34)
HbA1c, % (N = 34)
HbA1c, mmol ml−1 (N = 34)
Systolic BP (N = 34)
Diastolic BP (N = 34)
Foot conductance, avg (N = 20)b
Hand conductance, avg (N = 20)
MNSI-PA (N = 34)
NIS-LL (N = 34)
VAS (N = 34)
PGIC (N = 33)c
Quality of life total (N = 34)
SF McGill Pain Questionnaire Total (N = 34)
MNSI-Q (N = 34)
NTSS-6 Total (N = 34)
BDI (N = 34)
CESD-R (N = 34)

Table 2.
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Supplementary Table S3). Pain as measured by the Neuropathy
Total Symptom Score and visual analog pain scale declined in
both groups (P = 0.70 and 0.39, respectively). The intervention
group had signiﬁcant improvements for seven of the ten items on
the Neuropathic Pain Scale, but these differences were not
signiﬁcant between groups (Supplementary Table S4).
For the MNSI-PA, improvements were noted for both groups,
but did not reach statistical signiﬁcance for either group. For the
MNSI-Q, the improvement for the intervention group was
signiﬁcantly greater than the improvement for the control group.
For the Neuropathy Impairment Score-Lower Limb, the intervention group improved slightly, while the control group worsened,
but neither result was statistically signiﬁcant.
During the study, two intervention-group participants began
taking medications for neuropathy, and two eliminated such
medications. In the control group, one participant began and then
stopped taking pregabalin. Limiting the analysis of symptomrelated outcomes to participants who did not change symptom
management medications did not change the results, except that
changes in total Quality of Life score were no longer signiﬁcant
within the intervention group.
Changes in mood
No signiﬁcant changes were observed in the Beck Depression
Inventory or the Center for Epidemiological Studies Depression
revised scale over the 20 weeks.
DISCUSSION
In this 20-week diet intervention, body weight and body mass
index decreased more in the intervention group, and HbA1c
declined signiﬁcantly only in the intervention group. Electrochemical skin conductance in the foot declined in the control
group, but stayed essentially constant in the intervention group,
suggesting that the intervention may have slowed or halted
sudomotor nerve function decline. Signiﬁcant improvements in
pain were observed in the intervention group, as measured by the
Quality of Life questionnaire, Short Form McGill Pain Questionnaire, MNSI-Q and change in pain question. Improvements in selfreported worst pain were observed in the control group, and
improvements in Neuropathy Total Symptom Score were
observed in both groups.
Our ﬁndings, using a design including a control group with a
vitamin B12 supplement serving as a placebo control, are
consistent with those of previous, smaller studies showing
improvements in neuropathy pain and symptoms with a dietary
intervention. Crane and Sample11 enrolled 21 participants with
type 2 diabetes and painful neuropathy in a residential lifestyle
intervention program, using a reduced-calorie, low-fat, plantbased diet with exercise for 25 days. Complete remission of
burning pain and an improved sense of touch was reported by
81% of participants, while the remaining participants reported
partial symptomatic relief. Other favorable changes included
weight loss, decreased blood lipid concentrations and reduced
need for medications for blood pressure and blood glucose
control. That study was shorter in duration than the present study,
and had a higher-intensity intervention, including a residential
program with exercise. Since nerve damage occurs over the
course of years, a longer study might be expected to show greater
improvements in pain and neuropathy symptoms.
Smith et al.10 studied 32 individuals without diabetes but
with impaired glucose tolerance and peripheral neuropathy.
Participants were counseled on diet and exercise during the 1year study. Improvements in glucose tolerance, body weight and
cholesterol levels were accompanied by signiﬁcant increases in
intraepidermal nerve ﬁber density and foot sweat volume. Nonsigniﬁcant improvements in pain were observed. The intervention

in the present study was more intense, with weekly nutrition
education meetings, but had a shorter duration.
The mechanism(s) by which the low-fat plant-based diet
improves neuropathy pain may involve improved insulin sensitivity, leading to better glucose control.28 In addition, diabetic
neuropathy is associated with hypertension, dyslipidemia and
obesity, all of which can be ameliorated with a plant-based
diet.8,29,30
Adherence to the plant-based aspect of the diet was high, but
adherence the low-fat requirement of the diet was less so. A
previous review has shown that group support and frequent
monitoring of dietary adherence improve adherence to reducedfat diets, so those factors were included in this study.30
Medication changes in the intervention group may have
obscured some improvements in glucose control, blood lipids
and blood pressure. Most of the intervention-group participants
who altered diabetes medications did so because of hypoglycemia. It is possible that some changes in pain and other symptoms
were in part related to changes in symptom management
medication that occurred during the 20 weeks.
It is noteworthy that the control group reported signiﬁcant
improvements in self-reported worst pain (visual analog pain) and
symptoms as measured by the Neuropathy Total Symptom Score.
The magnitude of the improvement suggests that the B12
supplement, intended to serve as a placebo, may have had real
effects in both groups.16 Although all participants included in the
data analysis had acceptable B12 and MMA levels at baseline, it is
conceivable that some participants in both groups had increased
B12 activity as a result of the supplement. This may have caused
some of the observed improvements in the control group,
particularly since 72% of the control participants (13 of 18), were
metformin-treated, and B12 deﬁciency is more common in that
population.31 In addition, the control group had a higher baseline
mean body weight and a greater proportion of black or Hispanic
participants (15 of 18 participants, compared with 6 of 17 in the
intervention group). Among diabetes patients, blacks have a
higher risk of diabetic neuropathy.32 We also note that, as used in
the present study, the visual analog pain rated only ‘worst pain’
during the preceding 2-week period, and did not assess typical or
‘average’ pain.
This pilot study has several strengths. It used a randomized
design, a control group, and an adequate time frame for the
observation of clinical changes. It was conducted with community
volunteers; therefore, the results are readily translatable to
applications outside the research setting. A comparable previous
study11 was done as part of a residential program, in which food
was provided and exercise was mandatory. Those authors saw
dramatic improvements in a short time, but they did not
demonstrate that their intervention was sustainable or their
results generalizable.
The study also has weaknesses. Because the study was designed
to assess the efﬁcacy of the intervention on neuropathy pain and
related signs and not to determine which part of the intervention
was responsible for observed clinical changes, the effect of the
weekly classes cannot be separated from the effect of the diet. In
addition, the effects of the plant-based diet cannot be differentiated from the effects of weight loss it may cause. Further
studies are needed to identify the speciﬁc mechanisms by which
the intervention may lead to physical and symptomatic improvements. The self-reported nature of pain is an intrinsic limitation of
pain research. Although B12-deﬁcient participants were excluded,
we cannot be certain that the supplement, intended as a placebo,
did not have real effects. Also, the deﬁnition of painful diabetic
neuropathy as an inclusion criterion may have been insufﬁciently
precise; future trials should ensure that diagnostic criteria adhere
to current guidelines.
In conclusion, this pilot study suggests the potential of a dietary
approach for treating diabetic neuropathy and provides ﬁndings
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that can be used to guide further studies. This was the ﬁrst
randomized controlled study of diet and diabetic nerve pain, and
demonstrates that the effect of the diet is greater than a control
treatment for some outcomes.
Nutrition studies are particularly important given that drugs
used to manage blood glucose have signiﬁcant side effects, and
drugs used for diabetic nerve pain typically offer only limited
beneﬁt. Further studies might eliminate the confounding factor of
vitamin B12 status by including vitamin B12 pretreatment or an
alternative control, such as a subclinical dose of B12. A trial testing
diet, exercise and vitamin B12 in combination might be a useful
means of assessing the effects of a more intensive intervention in
this otherwise intractable and debilitating chronic disease.
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